Systematic review of the clinical development of group B streptococcus serotype-specific capsular polysaccharide-based vaccines

References

• Madrid L, Seale AC, Kohli-Lynch M, et al. Infant group b streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65(suppl2):S160–S72.
   PubMedGoogle Scholar
• Heath PT, Balfour GF, Tighe H, et al. Efstratiou a. Group B streptococcal disease in infants: a case control study. Arch Dis Child. 2009 Sep;94(9):674–680.
   PubMed Web of Science ®Google Scholar
• Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012 Jun 9;379(9832):2151–2161.
   PubMed Web of Science ®Google Scholar
• Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet. 2012 Jan 4;379(9815):547–556.
   PubMed Web of Science ®Google Scholar
• Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385(9966):430–440.
   PubMed Web of Science ®Google Scholar
• Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. 2008;299(17):2056–2065.
   PubMed Web of Science ®Google Scholar
• Deutscher M, Lewis M, Zell ER, et al. Incidence and severity of invasive Streptococcus pneumoniae, group A Streptococcus, and group B streptococcus infections among pregnant and postpartum women. Clin Infect Dis. 2011;53(2):114–123.
   PubMed Web of Science ®Google Scholar
• Winn HN. Group B streptococcus infection in pregnancy. Clin Perinatol. 2007 Sep;34(3):387–392.
   PubMed Web of Science ®Google Scholar
• Hall J, Adams NH, Bartlett L, et al. Maternal disease with group b streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65(suppl 2):S112–24.
   PubMedGoogle Scholar
• Kalin A, Acosta C, Kurinczuk JJ, et al. Severe sepsis in women with group B Streptococcus in pregnancy: an exploratory UK national case-control study. BMJ Open. 2015;5(10):e007976.
   PubMed Web of Science ®Google Scholar
• Nan C, Dangor Z, Cutland CL, et al. Maternal group B Streptococcus-related stillbirth: A systematic review. BJOG An Int J Obstet Gynaecol. 2015;122(11):1437–1445.
   PubMed Web of Science ®Google Scholar
• Bianchi-Jassir F, Seale AC, Kohli-Lynch M, et al. Preterm birth associated with group b streptococcus maternal colonization worldwide: systematic review and Meta-analyses. Clin Infect Dis. 2017;65(suppl 2):S133–S42.
   PubMedGoogle Scholar
• Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis. 2005 Sep 15; 41(6):839–847.
   PubMed Web of Science ®Google Scholar
• Patras KA, Nizet V. Group B streptococcal maternal colonization and neonatal disease: molecular mechanisms and preventative approaches. Front Pediatr. 2018;6(February):1–17.
   PubMedGoogle Scholar
• Ohlsson A, Shah V, Stade B. Vaginal chlorhexidine during labour to prevent early-onset neonatal group B streptococcal infection. Cochrane Database Syst Rev. 2014;12:CD003520.
   Google Scholar
• Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early- onset neonatal sepsis. Lancet Infect Diseses. 2003;3(4):201–213.
   PubMed Web of Science ®Google Scholar
• Romain AS, Cohen R, Plainvert C, et al. Clinical and laboratory features of group b streptococcus meningitis in infants and newborns: study of 848 Cases in France, 2001-2014. Clin Infect Dis. 2018;66(6):857–864.
   PubMed Web of Science ®Google Scholar
• Lancefield RC, Freimer EH. Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond). 1966 Jun;64(2):191–203.
   PubMedGoogle Scholar
• Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine. 1998;16(14–15):1391–1395.
   PubMed Web of Science ®Google Scholar
• Lancefield RC. A serological differentiation of human and other groups of hemolytic streptococci. J Exp Med. 1933;57(4):571–595.
   PubMedGoogle Scholar
• Slotved H-C, Kong F, Lambertsen L, et al. A proposed new streptococcus agalactiae serotype. J Clin Microbiol. 2007 Sep;45(9):2929–2936.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A phase 1/2, randomized, placebo-controlled, observer-blinded trial to evaluate the safety, tolerability, and immunogenicity of a multivalent group B streptococcus vaccine. In Healthy Adults 18 To 49 Years Of Age. Internet 2017 [cited 2018 Jan 24]. 1. Available from: https://clinicaltrials.gov/ct2/show/NCT03170609?cond=Group+B+Streptococcal+Infection&rank=2
   Google Scholar
• Dangor Z, Lala SG, Cutland CL, et al. Burden of invasive group B Streptococcus disease and early neurological sequelae in South African infants. PLoS One. 2015;10(4):1–13.
   Web of Science ®Google Scholar
• Heath PT, Feldman RG. Vaccination against group B streptococcus. Expert Rev Vaccines. 2005 Apr;4(2):207–218.
   PubMed Web of Science ®Google Scholar
• Schuchat A. Epidemiology of group B streptococcal disease in the United States : shifting Paradigms. Clin Microbiol Rev. 1998 Jul;11(3):497–513.
   PubMed Web of Science ®Google Scholar
• Heath PT. An update on vaccination against group B streptococcus. Expert Rev Vaccines. 2011 May;10(5):685–694.
   PubMed Web of Science ®Google Scholar
• Kwatra G, Adrian PV, Shiri T, et al. Serotype-specific cell-mediated immunity associated with clearance of homotypic group B streptococcus rectovaginal colonization in pregnant women. J Infect Dis. 2016;213(12):1923–1926.
   PubMed Web of Science ®Google Scholar
• Simister N. Placental transport of immunoglobulin G. Vaccine. 2003 Jul 28;21(24):3365–3369.
   PubMed Web of Science ®Google Scholar
• Dangor Z, Kwatra G, Izu A, et al. Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev Vaccines. 2015;14(1):135–149.
   PubMed Web of Science ®Google Scholar
• Kwatra G, Adrian PV, Shiri T, et al. Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women. Clin Microbiol Infect. 2015;21(6):1–9.
   Google Scholar
• Baker CJ, Rench MA, Edwards MS, et al. Immunization of pregnant women with a polysaccharide vaccine of group B Streptococcus. N Engl J Med. 1988;319(18):1180–1185.
   PubMed Web of Science ®Google Scholar
• Baker C. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine. 2003 Jul 28;21(24):3468–3472.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Maes C, Willekens J, et al. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women. Vaccine. 2016;34(15):1786–1791.
   PubMed Web of Science ®Google Scholar
• Donders GG, Halperin SA, Devlieger R, et al. Maternal immunization with an investigational trivalent group b streptococcal vaccine a randomized controlled trial. Obs Gynecol. 2016;127(2):213–221.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Cutland CL, Jose L, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016;3099(16):1–12.
   Google Scholar
• Heyderman RS, Madhi SA, French N, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis. 2016;3099(15):1–10.
   Google Scholar
• Baker CJ, Edwards MS, Kasper DL. Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest. 1978;61(4):1107–1110.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Kasper DL, Edwards MS, et al. Influence of preimmunization antibody levels on the specificity of the immune response to related polysaccharide antigens. N Engl J Med. 1980;303(4):173–178.
   PubMed Web of Science ®Google Scholar
• Brigtsen AK, Kasper DL, Baker CJ, et al. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. J Infect Dis. 2002;185(9):1277–1284.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Rench MA, Fernandez M, et al. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis. 2003 Jul 1;188(1):66–73.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Rench MA, et al. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis. 2004 Mar 15;189(6):1103–1112.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Rench MA, Paoletti LC, et al. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine. 2007 Jan 2;25(1):55–63.
   PubMed Web of Science ®Google Scholar
• Edwards MS, Lane HJ, Hillier SL, et al. Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine. 2012 Jun 13;30(28):4123–4126.
   PubMed Web of Science ®Google Scholar
• de Cueninck BJ, Eisenstein TK, McIntosh TS, et al. Quantitation of in vitro opsonic activity of human antibody induced by a vaccine consisting of the type III-specific polysaccharide of group B streptococcus. Infect Immun. 1983;39(3):1155–1160.
   PubMed Web of Science ®Google Scholar
• Eisenstein TK, de Cueninck BJ, Resavy D, et al. Quantitative determination in human sera of vaccine-induced antibody to type-specific polysaccharides of group B streptococci using an enzyme-linked immunosorbent assay. J Infect Dis. 1983;147(5):847–856.
   PubMed Web of Science ®Google Scholar
• Edwards MS, Fuselier PA, Rench MA, et al. Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination of a radioimmunoprecipitin assay. Infect Immun. 1984;44(2):257–261.
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Fattom A, Basham L, et al. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. Vaccine. 1996 Apr;14(5):446–450.
   PubMed Web of Science ®Google Scholar
• Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest. 1996 Nov 15;98(10):2308–2314.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis. 1999 Jan;179(1):142–150.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Rench MA, et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis. 2000 Oct;182(4):1129–1138.
   PubMed Web of Science ®Google Scholar
• Paoletti LC, Rench MA, Kasper DL, et al. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group b streptococcal type III conjugate vaccines. Infect Immun. 2001;69(11):6696–6701.
   PubMed Web of Science ®Google Scholar
• Palazzi DL, Rench MA, Edwards MS, et al. Use of type V group B streptococcal conjugate vaccine in adults 65–85 years old. J Infect Dis. 2004;190(3):558–564.
   PubMed Web of Science ®Google Scholar
• Edwards MS, Baker CJ, Kasper DL. Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. J Infect Dis. 1979;140(6):1004–1008.
   PubMed Web of Science ®Google Scholar
• Pannaraj PS, Edwards MS, Ewing KT, et al. Group B Streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation. Vaccine. 2009;27(233):4452–4456.
   PubMedGoogle Scholar
• Guttormsen H, Baker CJ, Nahm MH, et al. Type III Group B Streptococcal polysaccharide induces antibodies that cross-react with streptococcus pneumoniae type 14 type III Group B Streptococcal polysaccharide induces antibodies that cross-react with streptococcus pneumoniae type 14. Infect Immun. 2002;70(4):1724–1738.
   PubMed Web of Science ®Google Scholar
• Pannaraj PS, Kelly JK, Madoff LC, et al. Group B Streptococcus bacteremia elicits beta C protein-specific IgMand IgG in humans. J Infect Dis. 2007 Feb 1;195(3):353–356.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics. 1981 Oct;68(4):544–549.
   PubMed Web of Science ®Google Scholar
• Baker CJ, Carey VJ, Rench MA, et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis. 2014;209(5):781–788.
   PubMed Web of Science ®Google Scholar
• Fabbrini M, Rigat F, Rinaudo CD, et al. The protective value of maternal group b streptococcus antibodies: quantitative and functional analysis of naturally acquired responses to capsular polysaccharides and pilus proteins in european maternal sera. Clin Infect Dis. 2016;63(6):746–753.
   PubMed Web of Science ®Google Scholar
• Lin F-YC, Weisman LE, Azimi PH, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis. 2004 Sep 1;190(5):928–934.
   PubMed Web of Science ®Google Scholar
• Dangor Z, Kwatra G, Izu A, et al. Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants. Vaccine. 2015;33(48):6793–6799.
   PubMed Web of Science ®Google Scholar
• Keller-Stanislawski B, Englund JA, Kang G, et al. Safety of immunization during pregnancy: A review of the evidence of selected inactivated and live attenuated vaccines. Vaccine. 2014;32(52):7057–7064.
   PubMed Web of Science ®Google Scholar
• Dangor Z, Kwatra G, Izu A, et al. HIV-1 Is associated with lower group b streptococcus capsular and surface-protein IgG antibody levels and reduced transplacental antibody transfer in pregnant women. J Infect Dis. 2015;212:1–10.
   PubMed Web of Science ®Google Scholar
• Le Doare K, Allen L, Kampmann B, et al. Anti-Group B Streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infection. Vaccine. 2015;33(5):621–627.
   PubMed Web of Science ®Google Scholar
• Omer SB, Longo DL. Maternal immunization. N Engl J Med. 2017;376(13):1256–1267.
   PubMed Web of Science ®Google Scholar
• Abajobir AA, Abbafati C, Abbas KM, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–1210.
   PubMed Web of Science ®Google Scholar
• Larsson C, Lindroth M, Nordin P, et al. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed. 2006 Nov;91(6):F403–F8.
   PubMed Web of Science ®Google Scholar
• Baker C, Carey V, Edwards M. Women receiving group b streptococcus serotype III tetanus toxoid (GBS III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III. In: Infectious diseases society of America 47th annual meeting. Philadelphia, Pennsylvania; 2009.
   Google Scholar
• ClinicalTrials.gov. Safety and Immunogenicity of a Group B Streptococcus vaccine in non-pregnant women 18-40 years of age [Internet]. 2015 [cited 2018 Mar 9]. 1. Available from: https://clinicaltrials.gov/ct2/show/NCT02459262?term=Minervax&rank=1
   Google Scholar
• Martin D, Gagnon E, Boyer M, et al. Protection from Group B Streptococcal infection in neonatal mice by maternal immunization with recombinant sip protein. Infect Immun. 2002;70(9):4897–4901.
   PubMed Web of Science ®Google Scholar
• Meinke AL, Senn BM, Visram Z, et al. Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens. Vaccine. 2010 Oct 8;28(43):6997–7008.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Debol S, Lam H, et al. Immunization with C5a peptidase or peptidase-type iii polysaccharide conjugate vaccines enhances clearance of Group B Streptococci from lungs of infected mice. Infect Immun. 2002;70(11):6409–6415.
   PubMed Web of Science ®Google Scholar
• Nuccitelli A, Cozzi R, Gourlay LJ, et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. PNAS. 2011;108:10278–10283.
   PubMed Web of Science ®Google Scholar
• Dangor Z, Kwatra G, Izu A, et al. Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants. Expert Rev Vaccines. 2015;14(12):1651–1660.
   PubMed Web of Science ®Google Scholar
• Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016;388(10063):3027–3035.
   PubMed Web of Science ®Google Scholar
• Seale AC, Bianchi-Jassir F, Russell NJ, et al. Estimates of the burden of group b streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis. 2017;65(Suppl_2):S200–S19.
   PubMed Web of Science ®Google Scholar
• United Nations General Assembly. Transforming our world: the 2030 Agenda for Sustainable Development [Internet]. United Nations. 2015 [cited 2018 Jan 23]. Available from: https://sustainabledevelopment.un.org/post2015/transformingourworld
   Google Scholar
• Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine. 2013;31(Supplementary4):D52–D76.
   PubMedGoogle Scholar